Trial Search Results
Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)
In this study the investigators are trying to understand how immune function declines in the elderly using annual influenza vaccinations as a model system. The longitudinal study began in 2007 and continued through early 2017.
Stanford is currently not accepting patients for this trial.
Collaborator: National Institute of Allergy and Infectious Diseases (NIAID)
- Biological: Trivalent, inactivated influenza vaccine (TIV)
- Biological: Quadrivalent, inactivated influenza vaccine (IIV4)
- Biological: High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
- Age 18-30, 60-79, or 80-100 years, inclusive at time of initial enrollment
- General good health and ambulatory at time of enrollment
- No acute illness at time of vaccination
- Willing and able to sign Informed Consent
- Available for follow-up for the planned duration of the study
- Acceptable medical history by screening evaluation and brief clinical assessment
- All female subjects of childbearing potential must use an acceptable method of
contraception and not become pregnant for the duration of the clinical phase of the
study (approximately 1 month to completion of Visit 3). (Acceptable contraception may
include implants, injectables, combined oral contraceptives, effective intrauterine
devices (IUDs), sexual abstinence, or a vasectomized partner).
- Prior off-study vaccination with trivalent or quadrivalent (depending no year)
influenza vaccine (TIV or IIV4) or live attenuated influenza vaccine (LAIV) in the
current flu season
- Allergy to egg or egg products
- Allergy to vaccine components, including thimerosal
- Active systemic or serious concurrent illness, including febrile illness on the day of
- History of immunodeficiency
- Any chronic disorder which, in the opinion of the investigator, might jeopardize
volunteer safety or compliance with the protocol.
- Blood pressure >150 systolic or > 95 diastolic at Visit 1
- Chronic Hepatitis B or C.
- Recent or current use of systemic immunosuppressive medication, including
glucocorticoids (corticosteroid nasal sprays and inhaled steroids are permissible).
Use of oral steroids (<20mg prednisone-equivalent/day) may be acceptable after review
by the investigator.
- Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive
medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion
of the investigator, might jeopardize volunteer safety or compliance with the
- History of blood dyscrasias or hemoglobinopathies requiring regular medical follow up
or hospitalization during the preceding year
- Use of anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet
agents such as aspirin, Plavix, Aggrenox must be reviewed by investigator to determine
if this would affect the volunteer's safety.
- Receipt of blood or blood products within the past 6 months
- Medical or psychiatric condition or occupational responsibilities that preclude
subject compliance with the protocol
- Receipt of inactivated vaccine within 14 days prior to vaccination
- Receipt of live, attenuated vaccine within 60 days of vaccination
- History of Guillain-Barré Syndrome
- Pregnant or lactating woman
- Use of investigational agents within 30 days prior to enrollment
- Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment
- Any condition which, in the opinion of the investigator, might interfere with
volunteer safety, study objectives or the ability of the participant to understand or
comply with the study protocol.
Ages Eligible for Study
18 Years - 100 Years
Genders Eligible for Study